Clinical Trial Update: Avelumab in First-line NSCLC (JAVELIN Lung 100) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating first-line avelumab in non-small cell lung cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bavencio (avelumab) (avelumab)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: First Line Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-01-04